Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OMED

OncoMed Pharmaceuticals (OMED) Stock Price, News & Analysis

OncoMed Pharmaceuticals logo

About OncoMed Pharmaceuticals Stock (NASDAQ:OMED)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.89
$0.89
52-Week Range
N/A
Volume
1,201 shs
Average Volume
768,904 shs
Market Capitalization
$34.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive OMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OMED Stock News Headlines

Chase, Bank of America, Wells Fargo Preparing for BIG Change
Thanks to this brand-new law #S.1582 signed by President Trump… Jeff Brown believes the largest banks in America could soon begin to replace every single dollar in your bank account… With a better, more technologically advanced dollar… Potentially making a lot of people rich in the process.tc pixel
Bispecific Antibody Market Size | Statistics By 2031
See More Headlines

OMED Stock Analysis - Frequently Asked Questions

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) issued its quarterly earnings results on Thursday, November, 1st. The biopharmaceutical company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.36. The biopharmaceutical company had revenue of $19.52 million for the quarter, compared to analysts' expectations of $7.97 million. OncoMed Pharmaceuticals had a negative trailing twelve-month return on equity of 13.14% and a negative net margin of 18.24%.

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoMed Pharmaceuticals investors own include Esperion Therapeutics (ESPR), NXP Semiconductors (NXPI), Bristol Myers Squibb (BMY), Nightstar Therapeutics (NITE), GW Pharmaceuticals (GWPH), Celldex Therapeutics (CLDX) and Clovis Oncology (CLVS).

Company Calendar

Last Earnings
11/01/2018
Today
8/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OMED
CIK
1302573
Fax
N/A
Employees
22
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.16)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.10 million
Net Margins
-18.24%
Pretax Margin
N/A
Return on Equity
-13.14%
Return on Assets
-7.73%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.04
Quick Ratio
5.04

Sales & Book Value

Annual Sales
$44.42 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.25 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
38,690,000
Free Float
N/A
Market Cap
$34.43 million
Optionable
Optionable
Beta
1.86
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:OMED) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners